Editas Medicine names Charles Albright as chief scientific officer
Dr. Albright brings to Editas more than 25 years of life sciences industry and academic leadership experience, most recently serving as Vice President of Genetically Defined Diseases and Genomics at Bristol-Myers Squibb (BMS).
Over his career, Dr. Albright has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation.
Prior to his position as Vice President of Genetically Defined Diseases and Genomics, Dr. Albright held multiple scientific leadership roles in Neuroscience Biology at BMS.
Previously, he held positions at Incyte Corporation and DuPont Pharmaceuticals and was an Assistant Professor of Biochemistry at Vanderbilt University.
Dr. Albright received a Bachelor of Science in Chemical Engineering and a Ph.D. in Biology from the Massachusetts Institute of Technology (MIT). He was a postdoctoral fellow in the laboratory of Professor Robert Weinberg at the Whitehead Institute for Biomedical Research at MIT. ■
LATEST MOVES FROM Massachusetts
- PTC appoints Corinna Lathan to board
- J.Jill appoints James S. Scully to board
- Raytheon elects Robert O. Work as director
- Xenetic Biosciences appoints three directors
- Insulet appoints two to board
More inside POST